Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer [Phase 3]
Phase 3 study comparing brigatinib with alectinib in adults with ALK-positive non-small cell lung cancer has completed and posted results.
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Broncho-Vascular Lung Sparing Reconstructions and Pneumonectomies in Patients With Non Small Cell Lung Cancer
This clinical trial update describes a study evaluating broncho-vascular lung-sparing reconstructions and pneumonectomies in patients with n…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Primary Tumor Resection With EGFR TKI for Stage IV NSCLC [Phase 2]
Phase 2 trial evaluating primary tumor resection with an EGFR tyrosine kinase inhibitor for stage IV non-small cell lung cancer; the study i…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Effect of Omega 3 Enriched Oral Nutritional Supplement on Nutritional Status of CRC and NSCLC Patients [NA]
This completed clinical trial evaluated the impact of an Omega-3 enriched oral nutritional supplement on the nutritional status of colorecta…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Detection of Circulating Tumour Cells, Spread Through Air Space in Patients With Lung Cancer
This clinical trial is investigating the detection of circulating tumor cells and the spread through air space in patients with non-small ce…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2025-02-19Clinical Trial Update: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC [Phase 3]
Phase 3 trial evaluating whether time-of-day scheduling of immunochemotherapy affects progression-free survival in non-small cell lung cance…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer [Phase 3]
Phase 3 clinical study evaluating nanocrystalline megestrol in malnourished patients with first-line non-small cell lung cancer. The trial s…
-
CLINICAL_TRIALS trial_result · 2025-02-18Clinical Trial Update: Stage III NSCLC RWE in Chinese Patients
This clinical trial update reports completion of real-world evidence evaluating Stage III non-small cell lung cancer in Chinese patients, sp…
-
CLINICAL_TRIALS trial_result · 2025-02-18Clinical Trial Update: Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab in combination with plinabulin and docetaxel for metastatic non-small cell lung cancer after…
-
CLINICAL_TRIALS research · 2025-02-18Clinical Trial Update: Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
A clinical trial registry entry for a platform study evaluating molecular testing, treatment, and outcomes in non-small cell lung cancer and…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers [Phase 1, Phase 2]
Phase 1/2 trial update evaluating nivolumab plus ABI-009 (nab-rapamycin) in patients with advanced sarcoma and selected cancers, with result…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: BostonGene and Exigent Genomic INsight Study
Clinical trial update indicates that the BostonGene-Exigent Genomic INsight study is currently recruiting participants across indications in…
-
FDA approval · 2025-02-14FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) from Janssen Biotech, Inc., expanding its labeling or indications.
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine [Phase 1]
First-in-human Phase 1 study of OVM-200, a therapeutic cancer vaccine, being tested in prostate cancer, non-small cell lung cancer, and ovar…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating the combination of Vebreltinib and Osimertinib in advanced non-small cell lung cancer with an EGFR L858R m…
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]
This document provides a status update on an ongoing Phase 1/2 trial evaluating allogeneic PB103 natural killer (NK) cell therapy in non-sma…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) [Phase 2]
Phase 2 DENIVOS trial evaluating the combination of denosumab and nivolumab as second-line therapy for stage IV non-small cell lung cancer w…
-
EMA approval · 2025-02-13EMA Authorised: Docetaxel Accord (docetaxel) — Accord Healthcare S.L.U.
The EMA authorised Docetaxel Accord (docetaxel) from Accord Healthcare for multiple cancer indications, including head and neck cancer, non-…
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating durvalumab in combination with stereotactic radiotherapy for advanced Non-Small Cell Lung Cancer; the stud…
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies [Phase 1, Phase 2]
This document reports a Phase 1/Phase 2 clinical trial evaluating GV20-0251 as monotherapy and in combination with pembrolizumab in several …
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. [NA]
This clinical trial update describes an education intervention aimed at helping patients manage rash associated with epidermal growth factor…
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients [Phase 1]
Phase 1 clinical trial update on early prediction of therapeutic response to targeted therapy in stage IIIB/IV or recurrent non-small cell l…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients [Phase 3]
Durvalumab was studied as consolidation therapy in non-small cell lung cancer in a Phase 3 trial, with results posted in 2025. The results w…
-
EMA approval · 2025-02-12EMA Authorised: Pemetrexed Fresenius Kabi (pemetrexed) — Fresenius Kabi Deutschland GmbH
The EMA authorised Pemetrexed Fresenius Kabi (pemetrexed) for use in non-small cell lung cancer and malignant mesothelioma.
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function [Phase 1]
This is a Phase 1 pharmacokinetic study evaluating HS-10365 capsule in subjects with hepatic impairment and normal hepatic function, in the …